Eli Lilly's next-gen weight-loss drug crushes it — ride the momentum in pharma s
Thesis
Eli Lilly's new weight-loss drug data is impressing experts, which suggests the company's future revenue and earnings could be much higher than previously expected. When a major drug company successfully expands its portfolio of treatments, it often kicks off a sustained rally in the stock as mutual funds and large institutions increase their positions. Additionally, this positive news tends to lift the entire sector, creating potential opportunities in rival companies.
Strategy approach
Build a momentum strategy for LLY on the daily timeframe. Enter long when the stock's closing price is above its 10-day simple moving average and the volume on the breakout day exceeds the 20-day average volume. Exit the position if the closing price falls below the 10-day SMA, or implement a 5% trailing stop. Include an alternate entry for peers like NVO or AMGN using the same parameters.